A prospective study examining the effect of dienogest treatment on endometrioma size and symptoms

Yasemin Kızılkaya, Yasemin Kizilkaya, Mujde Can Ibanoglu, Müjde Can İbanoğlu, Şadıman Kıykaç Altınbaş, Sadiman Kıykac Altinbas, Yaprak Engin-Ustun, Yaprak Engin Üstün
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2022 · vol. 38(5) , pp. 403–406 · doi:10.1080/09513590.2022.2053956 · PMID:35319333 · W4221124180
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This study found that 3 months of daily oral dienogest treatment significantly reduced endometrioma size, pain symptoms, and improved quality of life in women with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Objective We aimed to determine the effect of dienogest on cyst volume, symptoms, and quality of life in patients with endometrioma.Method This prospective cohort study included 37 patients diagnosed with endometrioma and planned for medical treatment. Subjects were treated with a 3-month oral dose of dienogest 2 mg/day. Pre-treatment and post-treatment endometriosis measurements were assessed via 3D ultrasonography, pain symptoms via 100-mm visual analog scale (VAS), and quality of life via Short Form-36.Results The mean age of the patients was 36.0 ± 6.6 years. The mean endometrioma volume was significantly reduced by 31% after treatment (26.7 ± 19.7 mm3) compared to the pre-treatment volume (17.4 ± 11.2 mm3, p < .001). Post-treatment VAS scores of dysmenorrhea, dyspareunia, and chronic pelvic pain VAS values were significantly decreased by 35.5% (p < .001), 37.5% (p < .001), and 38.5% (p < .001), respectively. The mean physical function score and mental health score significantly increased by 15% (p = .009) and 28% (p < .001), respectively.Conclusion Our findings showed dienogest treatment at oral doses of 2 mg/day for 3 months significantly reducing the size of endometrioma, reducing pain level, and increasing quality of life in women with endometriosis.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

mesh:D004715mesh:D017699endometriosisendometriomachronic_pelvic_paindysmenorrheadyspareunia

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Nandrolone Nandrolone Nandrolone Nandrolone Nandrolone Nandrolone Nandrolone Nandrolone Nandrolone

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (26)

Cited by (5)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-22T00:35:11.618910+00:00
License: CC0 · commercial use OK